Business
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that University of Pittsburgh Medical Center's investigator-initiated trial evaluating LYMPHIR (denileukin diftitox-cxdl) in combination with the PD-1 immune checkpoint inhibitor pembrolizumab (KEYTRUDA®) has been selected for poster presentation at the American Society of Clinical O
About this update from Citius Oncology, Inc.
[{"type":"text","content":"24% Objective Response Rate, with an average of 21.1 month Duration of Response in responders, and favorable safety profile signals potential of LYMPHIR to augment immune checkpoint inhibitor efficacy ","length":200,"tagName":"p","attribs":{}},{"type":"text","content":"Investigator-initiated study of LYMPHIR in combination with pembrolizumab to be presented during immunotherapy session, highlighting potential role of LYMPHIR beyond CTCL","length":170,"tagName":"p","attribs":{}},{"type":"text","content":"CRANFORD, N.J., May 26, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that University of Pittsburgh Medical Center's investigator-initiated trial evaluating LYMPHIR (denileukin diftitox-cxdl) in combination with the PD-1 immune checkpoint inhibitor pembrolizumab (KEYTRUDA®) has been selected for poster presentation at the American Society of Clinical Oncology Annual Meeting (ASCO), taking place May 29 – June 2, 2026, in Chicago, Illinois.","length":657,"tagName":"p"},{"type":"image","alt":"Citius Oncology logo (PRNewsfoto/Citius Oncology, Inc.)","displaySize":"","headline":null,"caption":"Citius Oncology logo (PRNewsfoto/Citius Oncology, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":357,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/92b6ee873ab0a518804912f9102afc89"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zp3Rh_eVDszG6FJ1Viq6iw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTc5MA--/https://media.zenfs.com/en/prnewswire.com/92b6ee873ab0a518804912f9102afc89","width":357,"height":400},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/CueGH7LYKDPDt8Tdy5VZgg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTcxNw--/https://media.zenfs.com/en/prnewswire.com/92b6ee873ab0a518804912f9102afc89","width":357,"height":400}},"href":"https://mma.prnewswire.com/media/2588198/Citius_Oncology_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The abstract, submitted by investigators at the University of Pittsburgh Medical Center, was selected for presentation from more than 8,500 submissions reviewed by the ASCO Scientific Program Committee. The full abstract was made availabl...